Editas Medicine, Inc. EDIT entered into a definitive agreement with private biopharmaceutical company Shoreline Biosciences whereby the latter will license Editas’ proprietary SLEEK (SeLection by ...
Editas Medicine, Inc. EDIT has announced a corporate update, including the reprioritization of its current portfolio of pipeline candidates, and research and development realignment. The company will ...
First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data ...
Enhancing Immunotherapy and Cancer Research with Advanced CRISPR-Mediated Gene Editing EditCo Bio, Inc., a leader in genome engineering innovation, announced the expansion of its T-cell editing ...
Genome editing is poised to revolutionize our understanding and control of diverse biological systems. Critical to any genome editing workflow is monitoring the efficiency and accuracy of the steps ...
Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...
CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback